Key Highlights

  • ALVO shares traded up 2.49% to $5.16, versus a prior close of $5.03.
  • The FDA approved Process 2.0 for Simlandi, its Humira biosimilar.
  • The process more than doubles drug substance output per batch.
  • UBS raised its price target to $8 from $6 and kept a Buy rating.
  • Q3 results are due Nov. 12.

FDA Approves a Higher-Output Process for Simlandi

Alvotech (NASDAQ:ALVO) shares traded up 2.49% to $5.16 after the FDA approved a new manufacturing process for Simlandi, its biosimilar to Humira. Process 2.0 is introduced in the DSM2 suite in Reykjavik and more than doubles drug substance output per batch without changing the upstream manufacturing scale.

The company said comparability to the previous process was demonstrated while keeping product quality, safety and efficacy. The same quantity can now be made in fewer batches, freeing capacity for other products.

UBS Lifts Its Target as Capacity Expands

The approval follows an Oct. 5 approval of additional U.S. manufacturing capacity. UBS reiterated its Buy rating and raised its price target to $8 from $6, citing manufacturing progress, easing regulatory uncertainty, pending FDA decisions in December and a possible at-risk launch of its Simponi biosimilar with Teva (NYSE:TEVA).

Alvotech also filed the first known European application for an Eylea 8 mg biosimilar on Oct. 14.

A Biosimilar Platform Still Working Toward Steady Profits

Alvotech has five approved biosimilars and reported about $590 million in 2025 revenue, driven by strong European growth. It is not yet consistently profitable, with earnings per share at a loss of $0.59. The market capitalization is about $1.84 billion, and the stock remains well under its 52-week high of $8.53, against a low of $2.94.

Q3 Results on Nov. 12 Are the Next Update

Investors will watch for Q3 results on Nov. 12 and the pending FDA decisions in December. Volume was below average, so the move so far is modest.